GENELUX CORPORATION Debt Securities, Available-for-sale, Amortized Cost
GENELUX CORPORATION (GNLX) had Debt Securities, Available-for-sale, Amortized Cost of $9.49 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-13
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $9.49M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $16.94M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $9.26M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $16.22M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $9.49M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $16.94M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $9.26M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $16.22M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $21.43M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $18.87M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $22.27M 10-K · filed 2026-03-19 |
| 2024-09-30 | $28.84M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $32.60M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $15.57M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $13.76M 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |